(Q38210438)

31 August 2017

title

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease (English)

1 reference

31 August 2017

1 reference

1

Caroline M Perry

1 reference

31 August 2017

2

Greg L Plosker

1 reference

31 August 2017

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

771-792

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0215-7

31 August 2017

exact match

0 references

cites work

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Emerging effects of sevelamer in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer carbonate experience in Indian end stage renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Bile acid binding to sevelamer HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Cardiovascular effects of sevelamer in stage 3 CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Progression of cardiac valve calcification and decline of renal function in CKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

C-reactive protein and carotid and femoral intima media thickness: predicting inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Delayed progression to dialysis with early and intensive management of predialysis chronic kidney disease: a case-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer, a phosphate-binding polymer, is a non-absorbed compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Drug interaction between sevelamer and cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Phosphate control in dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer hydrochloride: an effective phosphate binder in dialyzed children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer therapy for pediatric end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Survival in end stage renal disease: calcium carbonate vs. sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Economic evaluation of sevelamer in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

An economic evaluation of sevelamer in patients new to dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0215-7

Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients

21 January 2018

1 reference

12 December 2020

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group

1 reference

12 December 2020

Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study

1 reference

12 December 2020

Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study.

1 reference

12 December 2020

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

1 reference

12 December 2020

Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer.

1 reference

12 December 2020

Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study

1 reference

12 December 2020

Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients

1 reference

12 December 2020

Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy

1 reference

12 December 2020

Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.

1 reference

12 December 2020

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

1 reference

12 December 2020

Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.

1 reference

12 December 2020

Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage

1 reference

12 December 2020

Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure

1 reference

12 December 2020

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients

1 reference

12 December 2020

Sevelamer worsens metabolic acidosis in hemodialysis patients

1 reference

12 December 2020

Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels

1 reference

12 December 2020

Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.

1 reference

12 December 2020

Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods

1 reference

12 December 2020

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

1 reference

12 December 2020

Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients

1 reference

12 December 2020

The clinical management of hyperphosphatemia

1 reference

12 December 2020

10.1007/S40265-014-0215-7

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1014254400

0 references

1 reference